The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape | Zendy

Peter J. Goebell | Zendy; Christian Doehn | Zendy; Carsten Grüllich | Zendy; Viktor Grünwald | Zendy; Thomas Steiner | Zendy; Rainer Ehneß | Zendy; Manfred Welslau | Zendy

Open Access

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape

Author(s) -

Peter J. Goebell,

Christian Doehn,

Carsten Grüllich,

Viktor Grünwald,

Thomas Steiner,

Rainer Ehneß,

Manfred Welslau

Publication year - 2017

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2017-0083

Subject(s) - everolimus , medicine , pazopanib , lenvatinib , nivolumab , renal cell carcinoma , oncology , tolerability , temsirolimus , adverse effect , discovery and development of mtor inhibitors , sunitinib , pi3k/akt/mtor pathway , cancer , immunotherapy , apoptosis , biochemistry , chemistry , thyroid cancer

VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research